J
Jennifer Sheng
Researcher at Bristol-Myers Squibb
Publications - 25
Citations - 773
Jennifer Sheng is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Nivolumab & Population. The author has an hindex of 10, co-authored 23 publications receiving 614 citations. Previous affiliations of Jennifer Sheng include Novartis & University of Michigan.
Papers
More filters
Journal ArticleDOI
Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant.
TL;DR: The results suggest that the KP dissolves very rapidly in small intestine, implying that its absorption will be predominantly controlled by gastric emptying, and only minimally limited by the subsequent dissolution processes, thus KP may be considered for possible waivers of bioequivalence.
Journal ArticleDOI
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Meletios A. Dimopoulos,Sagar Lonial,Darrell White,Philippe Moreau,Antonio Palumbo,Jesús F. San-Miguel,Ofer Shpilberg,Kenneth C. Anderson,Sebastian Grosicki,Ivan Spicka,Adam Walter-Croneck,Hila Magen,Maria-Victoria Mateos,Andrew R. Belch,Donna E. Reece,Meral Beksac,Eric Bleickardt,Valerie Poulart,Jennifer Sheng,Oumar Sy,Jessica Katz,Anil K. Singhal,Paul G. Richardson +22 more
TL;DR: ELd provided a durable and clinically relevant improvement in efficacy, with minimal incremental toxicity, in relapsed/refractory multiple myeloma and serum M‐protein dynamic modelling showed slower tumour regrowth with ELd.
Journal ArticleDOI
Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids.
TL;DR: The roles of lecithin and bile salts in a new generation of fasted simulated small intestinal fluid (FaSSIF-II) are evaluated, thus enhancing the closer mimic of simulated fluids to the real human intestinal fluids (HIF) in drug discovery and drug product development.
Journal ArticleDOI
Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors.
Jennifer Sheng,Shivani Srivastava,Kinjal Sanghavi,Zheng Lu,Brian J. Schmidt,Akintunde Bello,Manish Gupta +6 more
TL;DR: The ability of immuno‐oncology to meet its full potential will depend on overcoming development challenges, including the need for clear strategies to determine optimal dose and scheduling for monotherapy as well as combination approaches.
Journal ArticleDOI
Toward an In Vivo Dissolution Methodology: A Comparison of Phosphate and Bicarbonate Buffers
TL;DR: The substantial difference between pharmaceutical phosphates and physiological bicarbonates in determining the drug intrinsic dissolution rates of BCS II weak acids, such as ketoprofen and indomethacin is demonstrated.